Lenalidomide Medical Valley (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4‑CRBN E3 ubiquitin ligase complex, altering its substrate specificity. This leads to the ubiquitination and proteasomal degradation of transcription factors Ikaros and Aiolos, resulting in anti‑angiogenic effects, modulation of cytokine release, and enhanced immune‑mediated destruction of malignant cells.

The specific dose of Lenalidomide Medical Valley is determined by the prescribing clinician based on the patient’s diagnosis, disease stage, renal function, and prior therapies. Healthcare professionals tailor the regimen to achieve optimal efficacy while minimizing toxicity, and patients should follow the prescriber’s instructions exactly.

Lenalidomide is classified as contraindicated during pregnancy because it can cause fetal harm. Women of childbearing potential must use effective contraception before, during, and after treatment. Limited data exist for breastfeeding, and the drug is generally not recommended for nursing mothers due to potential exposure to the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and any required import documentation.

Lenalidomide belongs to the immunomodulatory drug (IMiD) class, similar to thalidomide and pomalidomide. Compared with thalidomide, lenalidomide has a more favorable side‑effect profile, especially regarding peripheral neuropathy, and offers stronger anti‑angiogenic and immune‑stimulating activity. Pomalidomide is a newer IMiD with activity in patients who have progressed after lenalidomide therapy.

Lenalidomide should be stored at ambient temperature, preferably below 25 °C (77 °F). Keep the product in its original blister or container, protect it from moisture, light, and excessive heat. Do not store in the bathroom or near a kitchen sink, and keep it out of reach of children.

Lenalidomide is taken orally, usually once daily, with or without food, as directed by the prescriber. The tablets should be swallowed whole with a glass of water. Patients should not split, crush, or chew the tablets unless specifically instructed, to maintain proper absorption and efficacy.

The most serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, severe neutropenia or thrombocytopenia that can lead to infection or bleeding, and the potential development of second primary malignancies. Patients should be monitored regularly for signs of clotting, low blood counts, and new cancer symptoms.

Lenalidomide should not be used by individuals who are pregnant, have uncontrolled active infections, or have a known hypersensitivity to lenalidomide or any of its excipients. Caution is also advised for patients with severe renal impairment, uncontrolled cardiovascular disease, or a history of thromboembolic disorders unless appropriate prophylaxis is in place.